CAMP PODS is a webinar series, consisting of three 1 hour events taking place on September 10th, October 1st  and November 5th.  The goal of this series is to build a strong Oncology Laboratory Medicine community, where best practices and common challenges can be discussed.  Insights gained will be key to implement across Canada and will help streamline laboratory workflows and practice for laboratory medicine, the end result of which will be improvements in the patient journey.


Thursday, September 10, 2020 – WATCH THE PODCAST
Chair: Dr. Diana Ionescu
10:00am – 10:30am PST What Oncologists Want- An Oncologic Pathology Hotline Dr. Barb Melosky &
Dr. Diana Ionescu
10:30am – 10:45am PST Panel Discussion
10:45am – 11:00am PST Questions & Answers
Presentation Learning Objectives:
As a result of attending this session the participant will be able to:
1. Reflect on the dynamic of oncologist-pathologist interactions
2. Project impactful adjustments in their collaboration with other specialists
3. Choose to actively open dialog with a clinical care team member
Thursday, October 1, 2020
Chair: Dr. Diana Ionescu
10:00am – 10:30am PST Cost Effective Biomarker Testing in Lung Cancer: The Alberta Experiment Dr. Cheryl Mather
10:30am – 11:00am PST Questions & Answers
Presentation Learning Objectives:
As a result of attending this session the participant will be able to:
1. Understand the biomarkers that meet current international guidelines for standard of care in lung
adenocarcinoma and be able to describe at least three other markers that  are being used in phase II-III trials.
2. Describe some of the challenges associated with step-wise testing for biomarkers in lung adenocarcinoma.
3. Analyze the pros and cons of a tiered testing system using MassArray and NGS for lung adenocarcinoma biomarker testing
Thursday, November 5, 2020
Chair: Dr. Diana Ionescu
10:00am – 10:30am PST Point of Care Molecular Testing Dr. Brandon Sheffield
10:30am – 11:00am PST Questions & Answers
Presentation Learning Objectives:
As a result of attending this session the participant will be able to:
1. Gain an appreciation for the urgency with which biomarker testing needs to be completed.
2. Identify ways that surgical pathology practice can facilitate cancer care in the clinic
3. Build familiarity with emerging techniques in molecular pathology


Diana N. Ionescu, MD, FRCP(C), FCAP

Consultant Pathologist, BC Cancer Agency
Medical Director Clinical Trials, BCCA VCC Laboratory
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC
Vancouver, BC

Dr. Ionescu is a graduate of University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania. She completed her postgraduate training in Anatomical and Clinical Pathology at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. She has practiced as a Consultant Pathologist at BC Cancer Agency in Vancouver since 2006. She is currently a Clinical Professor of Pathology at UBC and served as the residency program director for the Anatomic Pathology Residency Program between 2009 – 2017.

Her specific areas of diagnostic expertise are lung, gynecologic and breast pathology. She is an author of over 50 scientific publications and book chapters. She is the author and invited speaker at numerous regional, national and international lectures. Her investigation interests include oncologic pathology and molecular biomarkers, lung cancer and adult health education. She is the Canadian Anatomic and Molecular Pathology (CAMP) course director.

Dr. Ionescu is an enthusiastic advocate of pathologists participating in numerous patient education forums, TV shows, advocacy campaigns, being an Medical Advisor for Lung Cancer Canada and in 2015 appeared before the House of Commons Committee on Health.

Barbara Melosky, MD, FRCP(C)

Professor of Medicine, UBC
Medical Oncologist, BC Cancer
Vancouver, BC

Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.

Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.

She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.

Dr. Cheryl Mather

Clinical Lead, Molecular Pathology North
Alberta Precision Laboratories, Ltd.
University of Alberta Hospital,
Edmonton, AB

Dr. Mather is the medical lead for Molecular Pathology North.  Dr. Mather trained in molecular pathology at the University of California, San Francisco and in anatomic and clinical pathology and gastrointestinal and liver pathology at the University of Washington.  Dr. Mather’s interests are highly varied and include hereditary cancer, pancreatic neoplasia, and laboratory administration.  When she’s not working as a pathologist, Dr. Mather is the ringleader of her own circus of six kids.

Brandon Sheffield MD FRCP

Medical director of immunohistochemistry and molecular pathology
Physician lead of research
William Osler Health System
Brampton, ON

Dr. Brandon Sheffield is an anatomic and molecular pathologist with the William Osler Health System.  Dr. Sheffield specializes in the implementation and delivery of molecular diagnostics to guide cancer care.  His clinical and research interests explore ways to make molecular testing more accessible to cancer patients in a publicly-funded healthcare system.

Dr. Sheffield completed medical training at the University of Toronto, Pathology residency at the University of British Columbia, he is currently serving as the physician lead of research and medical director of immunohistochemistry and molecular pathology at the William Osler Health System.

CAMP PODS CME Accredited

“This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists-Association Canadienne des pathologistes. You may claim a maximum of 1.0 hour per session. (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.